Brief: PCI Biotech: Independent evaluation confirms promising signs of efficacy in Phase I/II bile duct cancer study
06/09/2016 07:00
Sept 6 (Reuters) - PCI Biotech Holding ASA PCIB.OL :
* Says independent evaluation confirms early promising signs of efficacy in the Phase I/II
bile duct cancer study
* Phase I part of study has been completed with good tolerability and promising early signs
of efficacy
Source text for Eikon: ID:nGNE2l3Z6t
Further company coverage: PCIB.OL
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on PCI Biotech Holding ASA
See all newsBrief: Euronext Oslo Børs To Delist PCI Biotech Holding Shares
Brief: Euronext Oslo Børs Gets Application From PCI Biotech Holding For Delisting
Brief: PCI Biotech Holding Board Proposes Dissolution, Delisting
Brief: Oslo Bors: PCI Biotech Holding Is Placed In Recovery Box
Brief: PCI Biotech Says Co Initiates Process To Evaluate Opportunity For Structured Wind-Up Process